Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Yang Yang, Li-Qin Tang & Wei Wei. (2013) Prostanoids receptors signaling in different diseases/cancers progression. Journal of Receptors and Signal Transduction 33:1, pages 14-27.
Read now
Read now
Justin VanHorn, Jeffrey D Altenburg, Kevin A Harvey, Zhidong Xu, Richard J Kovacs & Rafat A Siddiqui. (2012) Attenuation of niacin-induced prostaglandin D2 generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells. Journal of Inflammation Research 5, pages 37-50.
Read now
Read now
Anastazia Kei & Moses S Elisaf. (2012) Nicotinic acid: clinical considerations. Expert Opinion on Drug Safety 11:4, pages 551-564.
Read now
Read now
James M. McKenney. (2012) Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review. Postgraduate Medicine 124:1, pages 7-20.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Bruno Vergès. (2011) Combination lipid therapy in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, pages 1393-1403.
Read now
Read now
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, pages 649-661.
Read now
Read now
Articles from other publishers (8)
V. J. J. Schettler, C. L. Neumann, C. Peter, T. Zimmermann, U. Julius, B. Hohenstein, E. Roeseler, F. Heigl, P. Grützmacher, H. Blume, R. Klingel & A Vogt. (2019) Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clinical Research in Cardiology Supplements 14:S1, pages 33-38.
Crossref
Crossref
Aris P. Agouridis & Dimitri P. Mikhailidis. 2015. Combination Therapy In Dyslipidemia. Combination Therapy In Dyslipidemia
37
43
.
U. Julius & S. Fischer. (2013) Nicotinic acid as a lipid-modifying drug – A review. Atherosclerosis Supplements 14:1, pages 7-13.
Crossref
Crossref
K Mahdy Ali, A Wonnerth, K Huber & J Wojta. (2012) Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities. British Journal of Pharmacology 167:6, pages 1177-1194.
Crossref
Crossref
Lin-Zhang Huang & Hai-Bo Zhu. (2012) Novel LDL-oriented pharmacotherapeutical strategies. Pharmacological Research 65:4, pages 402-410.
Crossref
Crossref
Helen Vosper. (2011) Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters. Clinical Medicine Insights: Cardiology 5, pages CMC.S7601.
Crossref
Crossref
Mohamed H Ahmed. (2010) What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?. Journal of Cardiovascular Medicine 11:11, pages 858-860.
Crossref
Crossref
Maneesh Vasant Udiawar & Alan Rees. (2010) Therapy and clinical trials: nicotinic acid in the management of atherosclerotic disease. Current Opinion in Lipidology 21:3, pages 286-288.
Crossref
Crossref